MedPath

Effects of Cimetidine on Cisplatin-induced Nephrotoxicity.

Completed
Conditions
- irresectable and/or metastatic Head and Neck cancer.- treatment with Cisplatin.
Registration Number
NL-OMON21483
Lead Sponsor
Erasmus MC Rotterdam-Daniel den Hoed Cancer Center
Brief Summary

Sprowl et al. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther 2013;94(5):585-92

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

1. Histological or cytological confirmed diagnosis of any form of irresectable and/or metastatic Head and Neck cancer, which is not currently being treated with cisplatin;

2. Treatment with high doses of cisplatin (3-weekly 100 mg/m2), with radiotherapy. No other systemic anti-cancer treatment is allowed;

Exclusion Criteria

1. Pregnant or lactating patients; patients with reproductive potential must use a reliable method of contraception (excluding oral contraceptives), if required;

2. Serious illness or medical unstable condition requiring treatment, symptomatic CNS-metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To investigate the ability of cimetidine to prevent cisplatin-induced nephrotoxicity, while not impairing the efficacy of cisplatin in Head and Neck cancer patients.<br /><br>Urine and blood work will be done to establish baseline kidney function/damage.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath